We plan to study the urinary and fecal elimination profiles of both oral and intravenous [14C-6] 5-FU and its metabolites in the presence of 776C85. Eight cancer patients will be randomly assigned to receive either an intravenous dose or an oral solution of 5-FU labeled with tracer amount of [14C-6] 5-FU given by an alternative route of administration in period two. In both periods, patients will receive oral 766C85. Urine, fecal and blood levels of 5-FU and its catabolites will be measured for 48 hours at regular intervals.
|Effective start/end date||10/1/97 → 9/30/99|
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.